Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis.
Thomas N BurnLehn WeaverJulia E RoodNiansheng ChuAaron BodanskyPortia A KreigerEdward M BehrensPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
IFNγ is not necessary for the development of fulminant HLH, requiring physicians to consider case-by-case treatment strategies. Use of therapies that target upstream activators of CD8+ T cells, such as IL-33/ST2 signaling, may be more universally applicable treatment options that ameliorate both IFNγ-dependent and -independent manifestations of HLH/MAS.